. Author manuscript; available in PMC: 2019 Aug 23.

Published in final edited form as: Biometrics. 2019 Apr 3;75(2):371–381. doi: 10.1111/biom.12994

Table 4.

Simulation Parameters. True Eff-Tox parameters β^TR corresponding to the phase I-II scenarios in Table 3, and true mean survival time of each A(x₁), ⋯, A(x₅) for each phase I-II/III scenario’s null and alternative hypotheses.

Scenario	Eff-Tox Scen	Hyp	(β₁, β₂, $e^{β_{E}}$ , $e^{β_{T}}$ , β₀)^TR	( $μ_{A (x_{1})}$ , $μ_{A (x_{2})}$ , $μ_{A (x_{3})}$ , $μ_{A (x_{4})}$ , $μ_{A (x_{5})}$ )^TR
1	1	Null	(.1, −.5, .5, .5, 2.9)	(8.3, 17.9, 24, 22.5, 9.8)
1	1	Alt	(.25, −2, .5, .5, 3.4)	(1, 14.5, 36.2, 28.3, 1)
2	2	Null	(.1, −.1, 1, .5, 2.6)	(14.0, 17.8, 21.9, 23, 24)
2	2	Alt	(.5, 0, 1, .5, 2.3)	(7.1, 10.3, 16.0, 19.5, 36)
3	2	Null	(.1, −.5, .3, 1, 3.1)	(9.5, 18.5, 24, 22.5, 10.4)
3	2	Alt	(.1, −1, .3, 1, 3.6)	(6.9, 24.7, 38, 33.1, 6.3)
4	3	Null	(−.3, .3, .3, 1, 2.3)	(24,13.6, 8.9, 6.8,7.8)
4	3	Alt	(−.1, .3, .3, 1, 3.0)	(38, 24.6, 18.4, 15.0, 21.1)
5	3	Null	(.1, −.5, .3, .1, 3.0)	(9.3, 18.7, 24, 22.7, 10.4)
5	3	Alt	(.1, −1, .3, .1, 3.6)	(7.8, 28.8, 44, 38.6, 7.4)
6	1	Null	(.75, −.5, .3, .25, 2.8)	(3.2, 10.1, 20.4, 24, 20.4)
6	1	Alt	(1, −.6, .3, .25, 3.3)	(3.0, 12.9, 31.8, 40, 36.6)